PGNY Progyny, Inc.
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.…
Industry Peers
Healthcare PlansKey Statistics
About Progyny (NASDAQ: PGNY)
›
Progyny (NASDAQ: PGNY) is listed on Nasdaq, where its shares trade in USD. It belongs to the Healthcare Plans industry, part of the Healthcare sector, and reports about 835 employees.
The shares were at 35.71 USD on 20 November 2026, up 98.3% over 52 weeks. Its 52-week range is 16.10 USD to 37.20 USD: the price is 4.0% below the high and 121.8% above the low.
At a market capitalisation of 2.63B USD, it trades at 32.8 times trailing earnings and 14.9 times forward earnings. The median trailing P/E of its 9 largest Healthcare Plans peers is 19.4, a premium of 69% for PGNY.
Progyny reports return on equity of 11.3%, an operating margin of 10.0% and revenue up 8.9% year over year.
It holds more cash than debt, a net cash position of 169.73M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 12 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 37.75 USD is 5.7% above the current price. The next earnings report is expected on 25 February 2027.